A New Way to Predict Major Cardiac Events in Patients with Chronic Kidney Disease

November is National Diabetes Month, and this year’s theme is Diabetes Hits Different. This means that risk factors and complications can vary between individuals, but we can leverage new technologies and better resources to live our healthiest life.

The Link Between Diabetes and Chronic Kidney Disease

Patients with diabetes commonly develop Chronic Kidney Disease (CDK), affecting roughly 1 in 3 people with diabetes.

CKD can affect almost every part of your body, including your heart. When a person has CKD, their heart needs to pump harder to get blood to the kidneys, which can lead to heart disease.

Patients can lose up to 90% of their kidney function as CKD silently to kidney failure, requiring regular dialysis, which puts an even further strain on the heart. In fact, heart disease is the most common cause of death for someone on dialysis.

The Cost of CKD

With roughly 15% of the US population having CKD, the true cost of the disease is unfathomably large.

Current estimates by the American Heart Association show a staggering cost of $1.1 Trillion by 2035!

This further highlights the need for effective tools to prevent and manage further complications.

Stratifying Heart Disease Risk in Chronic Kidney Disease Patients

One breakthrough technology that has emerged is a simple AI-driven blood test that can predict an individual’s two-year risk of major cardiac events, Prevencio Inc’s HART CVE.

This groundbreaking risk assessment tool uses a sophisticated algorithm that combines well-established clinical data sets with certain protein levels to produce a patient-specific risk score that has been proven more accurate (86%) than standard of care tests.

Promising data from a 446-patient study was recently presented at the November 2022 American Heart Association’s Scientific Sessions.

The researchers from Massachusetts General Hospital tested patients undergoing coronary or peripheral angiogram, dividing them into risk categories from low to high risk, and predicted their two-year risk of stroke, heart attack, or cardiac death.

HART CVE was shown to be highly accurate, with a Hazard Ratio (HR) of 8.32. This means that patients with a high risk score were more than 8 times more likely to have a stroke, heart attack, or cardiac death, as compared to patients with a low risk score.

This promises to be an important tool in the future to help physicians stratify patient risk so appropriate intervention can be implemented.

About Prevencio

Prevencio has developed a useful tool in stratifying patient risk with their HART Cardiac Tests.

HART CADhs is designed to detect the risk of significant blockage in the heart artery. HART CVE provides a risk score for a patient’s 1-year risk of heart attack, stroke, or cardiac death, with 86% accuracy. It has also demonstrated high accuracy for 2-year risk in chronic kidney disease patients.

Prevencio is revolutionizing cardiovascular care with affordable, accessible, and highly accurate diagnostic testing.

Prevencio’s HART AI-driven blood tests are a breakthrough in cardiac care and prevention, employing AI to produce test panels of multiple proteins and clinical variables, combined with an algorithm to create a cardiovascular score.

To learn more or order test kits call (425) 576-1200.